Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix
Status:
Terminated
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
Objectives:
Primary:
To estimate the efficacy of bevacizumab and paclitaxel in patients with recurrent small cell,
large cell, and neuroendocrine cervical and uterine cancers, as measured by progression-free
survival.
Secondary:
1. To estimate the efficacy of bevacizumab and paclitaxel in patients with recurrent small
cell, large cell, and neuroendocrine cervical and uterine cancers, as measured by
overall survival.
2. To determine the response rates in patients with recurrent small cell, large cell, and
neuroendocrine cervical and uterine cancers when treated with bevacizumab and
paclitaxel.
3. To characterize the quality of life (QoL) in patients with recurrent small cell, large
cell, and neuroendocrine cervical and uterine cancers when treated with bevacizumab and
paclitaxel.
4. To determine the nature and degree of toxicity in patients with advanced or recurrent
small cell, large cell, or neuroendocrine cervical and uterine cancers when treated with
bevacizumab and paclitaxel.